76 related articles for article (PubMed ID: 30951590)
1. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
2. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
[TBL] [Abstract][Full Text] [Related]
3. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
McKeage K; Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(10):451-456. PubMed ID: 30459507
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y
Am J Hematol; 2024 Feb; 99(2):E55-E59. PubMed ID: 38165064
[No Abstract] [Full Text] [Related]
5. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Nichol JL
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
[TBL] [Abstract][Full Text] [Related]
6. Fostamatinib combined with TPO-RAs or steroids as a bridge to monotherapy or as time-limited continuous treatment in relapsed chronic ITP: A single-centre case series.
Passucci M; Laganà A; Donzelli L; Masucci C; Genoese A; Chistolini A; Baldacci E; Santoro C
Br J Haematol; 2024 May; 204(5):2129-2132. PubMed ID: 38563350
[No Abstract] [Full Text] [Related]
7. A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.
Alimova M; Sidhom EH; Satyam A; Dvela-Levitt M; Melanson M; Chamberlain BT; Alper SL; Santos J; Gutierrez J; Subramanian A; Grinkevich E; Bricio ER; Kim C; Clark A; Watts A; Thompson R; Marshall J; Pablo JL; Coraor J; Roignot J; Vernon KA; Keller K; Campbell A; Emani M; Racette M; Bazua-Valenti S; Padovano V; Weins A; McAdoo SP; Tam FWK; Ronco L; Wagner F; Tsokos GC; Shaw JL; Greka A
bioRxiv; 2020 Jun; ():. PubMed ID: 32637960
[TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.
Rolf MG; Curwen JO; Veldman-Jones M; Eberlein C; Wang J; Harmer A; Hellawell CJ; Braddock M
Pharmacol Res Perspect; 2015 Oct; 3(5):e00175. PubMed ID: 26516587
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia.
Yan S; Zhou H; Huang R; Wang F; Mei H; Lin L; Guo J; Zhou X; Li Z; Liu Y; Li S; Zhou W; Hou Y; Hou M
Am J Hematol; 2024 Mar; ():. PubMed ID: 38546375
[No Abstract] [Full Text] [Related]
10. American Society of Hematology 2019 guidelines for immune thrombocytopenia.
Neunert C; Terrell DR; Arnold DM; Buchanan G; Cines DB; Cooper N; Cuker A; Despotovic JM; George JN; Grace RF; Kühne T; Kuter DJ; Lim W; McCrae KR; Pruitt B; Shimanek H; Vesely SK
Blood Adv; 2019 Dec; 3(23):3829-3866. PubMed ID: 31794604
[TBL] [Abstract][Full Text] [Related]
11. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ; Izak M; Bussel JB
Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
[TBL] [Abstract][Full Text] [Related]
12. Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
Provan D; Arnold DM; Bussel JB; Chong BH; Cooper N; Gernsheimer T; Ghanima W; Godeau B; González-López TJ; Grainger J; Hou M; Kruse C; McDonald V; Michel M; Newland AC; Pavord S; Rodeghiero F; Scully M; Tomiyama Y; Wong RS; Zaja F; Kuter DJ
Blood Adv; 2019 Nov; 3(22):3780-3817. PubMed ID: 31770441
[TBL] [Abstract][Full Text] [Related]
13. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
14. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia.
Newland A; McDonald V
Immunotherapy; 2020 Dec; 12(18):1325-1340. PubMed ID: 33023353
[TBL] [Abstract][Full Text] [Related]
15. More about the combination of rituximab, cyclosporine and dexamethasone in the treatment of chronic ITP. A useful option on an environment with limited resources.
Thabet AF; Moeen SM
Platelets; 2020 Aug; 31(6):784-787. PubMed ID: 31603012
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
[TBL] [Abstract][Full Text] [Related]
17. Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment.
Al-Samkari H; Kuter DJ
Semin Thromb Hemost; 2020 Apr; 46(3):275-288. PubMed ID: 31830764
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
[TBL] [Abstract][Full Text] [Related]
19. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
